sorafenib has been researched along with toremifene in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (toremifene) | Trials (toremifene) | Recent Studies (post-2010) (toremifene) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 602 | 109 | 133 |
| Protein | Taxonomy | sorafenib (IC50) | toremifene (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.58 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
2 review(s) available for sorafenib and toremifene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |